Scarica l'app Stockscreener
6.14
2.16%
0.13
Dopo l'orario di chiusura:
6.24
0.10
+1.63%
Cingulate Inc Borsa (CING) Ultime notizie
CING SEC FilingsCingulate Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cingulate Adds Independent Director Jiang to Board Committees - The Globe and Mail
Cingulate appoints Zhanpeng Jiang to board of directors and key committees - au.investing.com
Cingulate Appoints Zhanpeng Jiang to Board of Directors - National Today
Zhanpeng Jiang joins Cingulate (CING) board with option for 15,000 shares - Stock Titan
Revenue Check: Can Cingulate Inc Equity Warrant sustain earnings growth2026 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Revenue Check: Is Cingulate Inc Equity Warrants ROE strong enough2026 Sector Review & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Earnings Miss: Can Cingulate Inc Equity Warrant maintain its current growth rate2026 AllTime Highs & Weekly Setup with High ROI Potential - baoquankhu1.vn
Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst - MSN
Cingulate (CING) registers 3.5M shares for Lincoln Park under $25M equity line - stocktitan.net
Falcon Creek discloses 28.5% Cingulate (CING) ownership stake - Stock Titan
Wall Street Recap: What is the target price for Cingulate Inc Equity Warrant stockMarket Trend Summary & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
FOMO Trade: Is Cingulate Inc currently under institutional pressureMarket Trend Report & Smart Money Movement Tracker - baoquankhu1.vn
Cingulate Announces ATM Equity Program and Share Issuance - The Globe and Mail
[EFFECT] Cingulate Inc. SEC Filing - Stock Titan
Can Cingulate Inc Equity Warrant sustain earnings growthWeekly Trade Review & Trade Opportunity Analysis - baoquankhu1.vn
Cingulate Inc. Enters ATM Sales Agreement with A.G.P./Alliance Global Partners for Common Stock Offering – March 2026 - minichart.com.sg
Cingulate Inc has submitted a prospectus supplement to the U.S. Securities and Exchange Commission, planning to conduct a market offering and sell common shares in phases for a total amount of up to 100 million dollars. - Bitget
Cingulate (NASDAQ: CING) adds $100M ATM share sale capacity - Stock Titan
Cingulate Inc. (NASDAQ: CING) launches up to $100M ATM sales program - Stock Titan
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Roth Capital Lowers Price Target for Cingulate (CING) to $14, Ma - GuruFocus
Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00 - marketbeat.com
Cingulate (NASDAQ: CING) files S-3/A amendment adding KPMG consent - Stock Titan
If You Invested $1,000 in Cingulate Inc (CING) - Stock Titan
History Review: Is Cingulate Inc likely to announce a buyback2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - MSN
What's going on with Cingulate stock today? - MSN
Stock Report: How cyclical is Cingulate Inc Equity Warrants revenue stream2026 Valuation Update & Long Hold Capital Preservation Plans - baoquankhu1.vn
CING: Laying the Foundation for 1H:27 Launch - Research Tree
What's Going On With Cingulate Stock Today? - Benzinga
3.5M-share resale registration by Cingulate (NASDAQ: CING) under Lincoln Park deal - Stock Titan
Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
Cingulate (CING) Expected to Announce Earnings on Thursday - MarketBeat
Cingulate Reports 2025 Financial Results, Advances CTx-1301 ADHD Drug with New Patents and NDA Progress - Minichart
Cingulate Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Bitget
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc. Advances Precision Timed Release ADHD and Anxiety Treatments with Innovative Drug Delivery Platform – 2025 Annual Report Highlights - Minichart
Cingulate (CING) outlines CTx-1301 FDA review, ADHD market and PTR pipeline - Stock Titan
Cingulate 10-K: $0 Revenue, $(22.45)M Net Loss - TradingView
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - Benzinga
CING: 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised - TradingView
CING: NDA for CTx-1301 accepted, $12M raised, and cash runway extends into late Q4 2026 - TradingView
CING: 2025 net loss widened to $22.4M; cash runway into late 2026, pending CTx-1301 FDA approval - TradingView
Patent wins and $12M PIPE support Cingulate (NASDAQ: CING) - Stock Titan
Cingulate Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Gains Report: How is Cingulate Inc managing supply chain issues2026 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Why did Cingulate stock skyrocket today? - CryptoRank
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):